Work

Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients

Year: 2019

Type: article

Study design: Observational Study

Source: European Journal of Cancer

DOI: 10.1016/j.ejca.2019.05.032

Authors: Zong-Han Yao, Wei-Yu Liao, Chao-Chi Ho, Kuan-Yu Chen, Jin-Yuan Shih, Jin-Shing Chen, Zhong-Zhe Lin, Chia-Chi Lin, James Chih-Hsin Yang, Chong-Jen Yu

Institutions: National Taiwan University, National Taiwan University Hospital

Language: English

Topic: Hepatitis B Virus Studies

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Bayer, Merck, Novartis, Roche, Celgene, AbbVie, Ono Pharmaceutical, Genentech, Merck Sharp and Dohme, Chugai Pharmaceutical

Award: G819453491

OpenAlex ID: W2955639089

FWCI: 3.804

Cites: 28

Cited by: 42

Related to: 10